» Articles » PMID: 27551545

The Pro-oxidative Drug WF-10 Inhibits Serial Killing by Primary Human Cytotoxic T-cells

Overview
Date 2016 Aug 24
PMID 27551545
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Cytotoxic T-cells (CTLs) play an important role in many immune-mediated inflammatory diseases. Targeting cytotoxicity of CTLs would allow to interfere with immune-mediated tissue destruction. Here we demonstrate that WF-10, a pro-oxidative compound, inhibits CTL-mediated cytotoxicity. WF-10 did not influence early steps of target-cell killing, but impaired the ability of CTLs to detach from the initial target cell and to move to a second target cell. This reduced serial killing was accompanied by stronger enrichment of the adhesion molecule LFA-1 in the cytolytic immune synapse. LFA-1 clustering requires activation of the actin-bundling protein L-plastin and was accordingly diminished in L-plastin knockdown cells. Interestingly, WF-10 likely acts through regulating L-plastin: (I) It induced L-plastin activation through phosphorylation leading to enhanced LFA-1-mediated cell adhesion, and, importantly, (II) WF-10 lost its influence on target-cell killing in L-plastin knockdown cells. Finally, we demonstrate that WF-10 can improve immunosuppression by conventional drugs. Thus, while cyclosporine A alone had no significant effect on cytotoxicity of CTLs, a combination of cyclosporine A and WF-10 blocked target-cell killing synergistically. Together, our findings suggest that WF-10 - either alone or in combination with conventional immunosuppressive drugs - may be efficient to control progression of diseases, in which CTLs are crucially involved.

Citing Articles

Expression of non-phosphorylatable S5A-L-plastin exerts phenotypes distinct from L-plastin deficiency during podosome formation and phagocytosis.

Lin X, Krishnamoorthy P, Walker E, Joshi H, Morley S Front Cell Dev Biol. 2023; 11:1020091.

PMID: 37138794 PMC: 10150066. DOI: 10.3389/fcell.2023.1020091.


Expression of TRX1 optimizes the antitumor functions of human CAR T cells and confers resistance to a pro-oxidative tumor microenvironment.

Balta E, Janzen N, Kirchgessner H, Toufaki V, Orlik C, Liang J Front Immunol. 2023; 13:1063313.

PMID: 36591284 PMC: 9794734. DOI: 10.3389/fimmu.2022.1063313.


Efficient T Cell Migration and Activation Require L-Plastin.

Joshi H, Morley S Front Immunol. 2022; 13:916137.

PMID: 35844504 PMC: 9277003. DOI: 10.3389/fimmu.2022.916137.


Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.

Balta E, Wabnitz G, Samstag Y Int J Mol Sci. 2021; 22(11).

PMID: 34072260 PMC: 8199456. DOI: 10.3390/ijms22115736.


Redox Regulation of the Actin Cytoskeleton in Cell Migration and Adhesion: On the Way to a Spatiotemporal View.

Balta E, Kramer J, Samstag Y Front Cell Dev Biol. 2021; 8:618261.

PMID: 33585453 PMC: 7875868. DOI: 10.3389/fcell.2020.618261.


References
1.
Yingsakmongkol N, Maraprygsavan P, Sukosit P . Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial. J Foot Ankle Surg. 2011; 50(6):635-40. DOI: 10.1053/j.jfas.2011.05.006. View

2.
Liblau R, Wong F, Mars L, Santamaria P . Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity. 2002; 17(1):1-6. DOI: 10.1016/s1074-7613(02)00338-2. View

3.
Das R, Bassiri H, Guan P, Wiener S, Banerjee P, Zhong M . The adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation. Blood. 2013; 121(17):3386-95. PMC: 3637014. DOI: 10.1182/blood-2012-11-468868. View

4.
Kuhne L, Konstandin M, Samstag Y, Meuer S, Giese T, Watzl C . WF10 stimulates NK cell cytotoxicity by increasing LFA-1-mediated adhesion to tumor cells. J Biomed Biotechnol. 2011; 2011:436587. PMC: 3100581. DOI: 10.1155/2011/436587. View

5.
McGrath M, Kahn J, Herndier B . Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs. 2002; 3(3):365-73. View